Navigation Links
Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study
Date:9/16/2010

Cambridge, Mass., September 15, 2010 bluebird bio (formerly Genetix Pharmaceuticals Inc.) an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.

The patient, who had been transfusion dependent since early childhood, has become transfusion independent for the past 21 months more than two years after treatment with the LentiGlobin vector. The study also identified a subset of cells with the corrected beta-globin gene that overexpressed a truncated form of a gene called HMGA2. The patient has not experienced any adverse events. The data show that while early on, the HMGA2 clone was a significant portion of the corrected cells, the clone levels had declined at the time the paper was prepared, and further follow up indicates the decline is continuing.

"Although based on the first treated patient, we believe these results are impressive and illustrate for the first time the significant potential for treatment of beta hemoglobinopathies using lentiviral beta-globin gene transfer in the context of autologous stem cell transplant," said Philippe Leboulch, M.D., senior author of the study and head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; professor of medicine, University of Paris; and visiting professor, Harvard Medical School. "For beta-thalassemia, we have worked intensely for almost 20 years to design, develop and manufacture LentiGlobin to provide a sustained high level hemoglobin production, resulting in a major clinical benefit. It has been very rewarding to follow this patient as his life has dramatically improved since receiving our treatment."

"For the first time, a patient with sev
'/>"/>

Contact: Dan Budwick
dan@purecommunicationsinc.com
973-271-6085
Pure Communications Inc.
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Nature study shows how molecules escape from the nucleus
2. Quantum computer a stage closer with silicon breakthrough, reports Nature journal
3. Study sheds light into the nature of embryonic stem cells
4. Muscular protein bond -- strongest yet found in nature
5. Nature parks can save species as climate changes
6. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
7. Cell Biosciences Announces Publication in Nature Medicine
8. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
9. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
10. Light-speed nanotech: Controlling the nature of graphene
11. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... ULURU Inc. (Amex:,ULU) today announced that it ... Food and Drug Administration (FDA) for Altrazeal(TM) Silver., ... have shown that,superior healing rates in numerous porcine ... dressings. Additionally, in toxicology and,in vitro bacteria inhibition ...
... (DIA) will host two co-located conferences from October 23-24 ... ... Horsham, PA (PRWEB) September 30, 2008 -- ... co-located conferences from October 23-24 in Washington DC. ...
... 30 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) ... on October 3, 2008. The investor day will provide ... regulatory milestones,for the Company. Additionally, Alessandro Gianni, M.D., Director ... University of Milan,who has authored over 300 publications will ...
Cached Biology Technology:ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 2ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 3DIA Co-located Conference to Examine Outsourcing and Project Management Best Practices 2Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008 2
(Date:4/18/2014)... survey of emergency contraceptive pills in Peru found ... either of substandard quality or falsified. Many pills ... the wrong active ingredient. One batch had no ... the fake drugs, researchers at the Georgia Institute ... spectrometry to quickly assess suspected counterfeit drugs and ...
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... (SSB) and Adolf Kühner AG ,- Prototype of orbital ... Mai 2009 / b3c newswire / – ExcellGene ... biopharmaceutical industry, expands its product offering with the introduction ... rely on orbital shaking principles for mixing compared ...
... a patient,s healthy tissue as well as eradicating the ... especially invasive and often causing nasty side effects. ... more precise and accurate treatment for cancerous tumours by ... Real-time image-guided radiotherapy, combining radiation treatment with non-invasive MR ...
... Medical College of Georgia nurse researcher is among the first ... funding through the American Recovery and Reinvestment Act of 2009. ... jobs and the research of African-Americans in the Augusta community ... seeks to create or save more than 3.5 million jobs ...
Cached Biology News:ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3MCG researcher among first to receive NIH stimulus funding 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... and pressurized syringe holder for any researcher who ... rate Microinjecting Fine microliter delivery ... to any new or existing perfusion rig - ... Connect to house air or a compressor (30 ...
Biology Products: